Streetbeat News

Stock Prices

LTBR

Lightbridge (NASDAQ:LTBR) reported a Q2 EPS loss of $(0.17), a 21.43% decrease from the $(0.14) loss per share in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:02 pm

SAVA

Cassava Sciences, Inc. (NASDAQ:SAVA) saw a significant stock price increase after announcing an extension of its open-label extension trials for its Alzheimer's treatment, simufilam. The extension aims to provide continuous treatment for patients and gather more long-term data. The company is also conducting two major Phase 3 studies, with results expected in 2024 and 2025.

Portfolio Pulse from Vaishali Prayag

July 31, 2024 | 9:01 pm

OLO

Olo shares are trading higher after the company reported better-than-expected Q2 sales results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:01 pm

AUR

Aurora Innovation, Inc. (NASDAQ:AUR) has announced a proposed public offering of $350 million in Class A common stock. The company has also canceled its business review conference call due to the commencement of this offering.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:01 pm

AXS

Axis Capital Holdings (NYSE:AXS) received mixed analyst ratings over the last quarter, with a majority being bullish. Analysts have set a 12-month price target range of $63.00 to $90.00, with an average target of $80.4, up from $74.80. The company's financial performance shows positive revenue growth and strong profitability metrics, though it carries a higher debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 9:01 pm

MAX

MediaAlpha shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:00 pm

AVDL

Avadel Pharmaceuticals (NASDAQ: AVDL) has announced the dosing of the first patient in its Phase 3 REVITALYZ trial for LUMRYZ, an extended-release oral suspension aimed at treating idiopathic hypersomnia.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:00 pm

VAL

Valaris (NYSE:VAL) reported Q2 2024 adjusted EPS of $2.03, significantly beating the analyst estimate of $0.71. The company also reported sales of $610 million, surpassing the $578.12 million estimate.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:00 pm

EPR

EPR Properties has confirmed its FY24 FFO as adjusted per share guidance to be in the range of $4.76 to $4.96, with an estimate of $4.85.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:00 pm

IMRX

Immuneering Corporation (NASDAQ:IMRX) has been granted FDA Fast Track designation for its lead program, IMM-1-104, as a first-line treatment for pancreatic ductal adenocarcinoma (PDAC). This follows a previous Fast Track designation for second-line treatment. The company expects initial data from its Phase 2a trial in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:59 pm